Century Therapeutics updates pipeline; CNTY-101 achieves 40% CRR at higher doses; SLE trial starts Q3 2024

Century Therapeutics, Inc.

CNTY-101 ELiPSE-1 Phase 1 data: 30% CRR, 40% ORR overall; 40% CRR, 60% ORR at highest dose levels in Schedule A.
CNTY-101 shows favorable safety: no GvHD, low-grade CRS/ICANS, manageable outpatient administration.
Phase 1 CALiPSO-1 trial for SLE (systemic lupus erythematosus) initiated early Q3 2024; initial data expected by YE 2024.
Cash of $249.9M at 1Q24 end provides runway into 2026.
Pursuing additional autoimmune regulatory submissions for CNTY-101 in 2H 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.